Mrinal Gounder
Associate Professor of Medicine
Medicine
581 publications
20,390 citations
51 h-index
Medicine
Rising Papers (1)
2025-01-06 · Nature Communications · Molecular Biology
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Mrinal M. GounderAssociate Professor of Medicine · Medicine
27 citations · 19.6x expected for field
Top Papers (1)
2019-01-08 · Nature Genetics · Oncology
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Mrinal M. GounderAssociate Professor of Medicine · Medicine
247.9x expected for field · 4,318 citations
Recent Papers (8)
2026-03-25 · Nature Communications · Molecular Biology
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal M. GounderAssociate Professor of Medicine · Medicine
2026-03-01 · ESMO rare cancers. · Rheumatology
203P Efficacy of nirogacestat in improving sleep outcomes in adults with desmoid tumors: Post hoc analysis from the DeFi trial
2026-03-01 · ESMO rare cancers. · Rheumatology
124P Efficacy of nirogacestat in improving emotional impact outcomes in adults with desmoid tumors: Post hoc analysis from the DeFi Trial
2026-02-26 · JCO oncology advances. · Pulmonary and Respiratory Medicine
Systemic Therapy Outcomes for Soft Tissue Leiomyosarcoma Patients in an Era of Next-Generation Sequencing
Mrinal M. GounderAssociate Professor of Medicine · Medicine
2026-02-12 · Clinical Cancer Research · Oncology
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma
Mrinal M. GounderAssociate Professor of Medicine · Medicine
2025-12-01 · ESMO rare cancers.
IMPACT OF PRIOR SYSTEMIC THERAPY ON TAZEMETOSTAT EFFICACY IN ADVANCED EPITHELIOID SARCOMA: POST HOC ANALYSIS OF STUDY EZH-202
Mrinal M. GounderAssociate Professor of Medicine · Medicine
2025-12-01 · ESMO rare cancers.
ASSOCIATION OF CLINICO-PATHOLOGIC FEATURES AND MOLECULAR GENOTYPES WITH OUTCOMES OF SYSTEMIC THERAPY IN METASTATIC SOFT TISSUE LEIOMYOSARCOMA (LMS) PATIENTS
Mrinal M. GounderAssociate Professor of Medicine · Medicine
2025-12-01 · ESMO rare cancers.
SAFETY AND EARLY EFFICACY OF VT3989, A TEAD INHIBITOR, IN PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): A PHASE I/II STUDY
Mrinal M. GounderAssociate Professor of Medicine · Medicine